Breast Cancer: Basic and Clinical Research 2014:8 81-88
Published on 12 May 2014
Sign up for email alerts to receive notifications of new articles published in Breast Cancer: Basic and Clinical Research
Tyrosine kinase inhibitors have revolutionized the oncology community and were pioneered by the use in HER2-targeted therapies. Improved outcomes were seen with the advent of trastuzumab, leading investigators to develop newer agents to target the HER2 pathway such as the novel monoclonal antibody pertuzumab. In this paper, we describe the attributes of pertuzumab including: mechanism of action, pharmacokinetics and metabolism, safety/cardiotoxicity, drug interactions, efficacy, and role in HER2-positive breast cancer management. Newly reviewed here versus previously published reviews on pertuzumab oriented therapy are data of pertuzumab monotherapy as it is used in combination with other anti-HER2 agents derived from preclinical research and ongoing clinical trials.
Materials and methods: A computer based literature search was carried out using PubMed data reported at international meetings (ASCO) up to September 2013 were included.
PDF (827.51 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
We are delighted about the speedy and professional process.
Facebook Google+ Twitter
Pinterest Tumblr YouTube